Využití kontinuálního zaslepeného monitoringu (CGMS) k vyhodnocení glykemií u pacientky s diabetes mellitus 1. typu léčené inzulíny degludek (Tresiba 200 U/ml) a aspart (Fiasp)

Title in English The use of a blinded Continuous Glucose Monitoring System (CGMS) for assessing glu¬cose levels in a patient with the type 1 diabetes mellitus treated with insulin degludec (Tresiba 200 U/m1) and aspart (Fiasp)


Year of publication 2020
Type Article in Periodical
Magazine / Source Kazuistiky v diabetologii
MU Faculty or unit

Faculty of Medicine

Keywords type 2 diabetes mellitus, continuous glucose monitoring, insulin therapy, insulin degludec
Description Insulin treatment requires regular glucose monitoring. Patients with the type 1 diabetes mel¬litus (DM) are offered an option to add or even replace the traditional method of a routine self-monitoring (SMBG) measurement by a continuous glucose monitoring system (CGMS). CGMS may be used as a retrospective/blinded system, continuous/open system and flash monitoring. CGMS was used for assessing the treatment with basal insulin analogues in the presented case report. The blinded system of measuring was chosen, during which the patient couldn't see the continuous glucose levels. The collected levels were only known retrospectively, after the end of monitoring, when they were loaded into the computer and used for assessing further insulin dose adjustment. CGMS lasted for 8 days. The aim of the presented case report was to understand the trend in glucose levels after the initiation of the treatment with the second-generation basal insulin analogue degludec (Tresiba 200 U/mL) in a combination with insulin aspart (Fiasp).

You are running an old browser version. We recommend updating your browser to its latest version.

More info